Research programme: aptamer-based therapeutics - Archemix/Ionis
Latest Information Update: 04 Nov 2017
At a glance
- Originator Isis Pharmaceuticals
- Developer Archemix Corporation
- Class Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 07 Apr 2011 Research is ongoing in USA